Skip to main content
Erschienen in: Der Pneumologe 4/2015

01.07.2015 | Journal Club

Keine Vorteile durch VAT-PP gegenüber der klassischen Talkum-Pleurodese im palliativen Setting

verfasst von: Dr. P. Zardo, H. Busk, I. Kutschka

Erschienen in: Zeitschrift für Pneumologie | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Auszug

Rintoul RC, Ritchie AJ, Edwards JG, Waller DA et al (2014) Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 384:1118–1127 …
Literatur
2.
Zurück zum Zitat Stahel RA, Weder W, Lievens Y et al (2010) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v126–v128PubMedCrossRef Stahel RA, Weder W, Lievens Y et al (2010) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v126–v128PubMedCrossRef
3.
Zurück zum Zitat Marinaccio A, Binazzi A, Cauzillo G et al (2007) Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 43:2722–2728PubMedCrossRef Marinaccio A, Binazzi A, Cauzillo G et al (2007) Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 43:2722–2728PubMedCrossRef
4.
Zurück zum Zitat Perrot M de, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413–1418PubMedCrossRef Perrot M de, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413–1418PubMedCrossRef
5.
Zurück zum Zitat Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260(4):577–580PubMedCentralPubMedCrossRef Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260(4):577–580PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Treasure T, Lang-Lazdunski L, Waller D (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772PubMedCentralPubMedCrossRef Treasure T, Lang-Lazdunski L, Waller D (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Weder W, Stahel RA, Baas P et al (2011) The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 12:1093–1094 (author reply 4–5)PubMedCrossRef Weder W, Stahel RA, Baas P et al (2011) The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 12:1093–1094 (author reply 4–5)PubMedCrossRef
8.
Zurück zum Zitat Cao CQ, Yan TD, Bannon PG et al (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5:1692–1703PubMedCrossRef Cao CQ, Yan TD, Bannon PG et al (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5:1692–1703PubMedCrossRef
9.
Zurück zum Zitat Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 145:909–910PubMedCrossRef Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 145:909–910PubMedCrossRef
10.
Zurück zum Zitat Mujoomdar AA, Sugarbaker DJ (2008) Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 20:298–304PubMedCrossRef Mujoomdar AA, Sugarbaker DJ (2008) Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 20:298–304PubMedCrossRef
Metadaten
Titel
Keine Vorteile durch VAT-PP gegenüber der klassischen Talkum-Pleurodese im palliativen Setting
verfasst von
Dr. P. Zardo
H. Busk
I. Kutschka
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Pneumologie / Ausgabe 4/2015
Print ISSN: 2731-7404
Elektronische ISSN: 2731-7412
DOI
https://doi.org/10.1007/s10405-014-0857-x

Weitere Artikel der Ausgabe 4/2015

Der Pneumologe 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.